NCT06953999 2026-03-04
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Akeso
Phase 3 Recruiting
Clinical Trials
68 trialsNCT06608927 2026-02-27
PRISM-1
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT06998940 2026-02-20
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT07383922 2026-02-04
A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3 Not yet recruiting
NCT06958328 2026-02-02
LAP100
NRG Oncology
Phase 3 Recruiting
NCT07272109 2025-12-15
PTCA199-16
Fudan University
Phase 3 Not yet recruiting
NCT06625320 2025-12-12
RASolute 302
Revolution Medicines, Inc.
Phase 3 Active not recruiting
NCT07262567 2025-12-03
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 3 Not yet recruiting
NCT07079228 2025-09-23
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT03750669 2025-05-13
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Completed
NCT01746979 2025-05-11
MAESTRO
ImmunoGenesis
Phase 3 Completed
NCT06571461 2024-08-27
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT01231347 2024-07-16
GAMMA
NantCell, Inc.
Phase 3 Completed
NCT01827553 2024-04-11
CONKO-007
University of Erlangen-Nürnberg Medical School
Phase 3 Completed
NCT02395016 2024-04-04
A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT04674956 2024-04-02
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
RenJi Hospital
Phase 3 Recruiting
NCT06217042 2024-01-22
HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer
Fudan University
Phase 3 Not yet recruiting
NCT02539537 2024-01-09
NEOPAN
UNICANCER
Phase 3 Completed
NCT06017284 2023-11-24
PTCA199-5
Fudan University
Phase 3 Recruiting
NCT02993731 2023-11-15
CanStem111P
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT00057876 2023-07-05
Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT01964430 2023-06-28
apact
Celgene
Phase 3 Completed
NCT03126435 2023-05-06
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
SynCore Biotechnology Co., Ltd.
Phase 3 Completed
NCT04969731 2021-11-22
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
GC Cell Corporation
Phase 3 Recruiting
NCT01956812 2021-08-16
PANCRIT®-1
Gilead Sciences
Phase 3 Terminated
NCT03766295 2020-12-08
Masitinib Plus Gemcitabine in Pancreatic Cancer
AB Science
Phase 3 Completed
NCT01072981 2020-05-28
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Lumos Pharma
Phase 3 Completed
NCT01836432 2020-05-28
PILLAR
Lumos Pharma
Phase 3 Terminated
NCT02043288 2020-04-15
Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer
Orient Europharma Co., Ltd.
Phase 3 Completed
NCT00026338 2020-04-02
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00844649 2019-11-25
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Celgene
Phase 3 Completed
NCT01314027 2019-07-25
Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer
University of Zurich
Phase 3 Terminated
NCT00789633 2018-12-17
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
AB Science
Phase 3 Completed
NCT01900327 2018-05-11
NEOPA
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Terminated
NCT01077427 2017-11-17
HEAT
Klinikum der Universitaet Muenchen, Grosshadern
Phase 3 Unknown
NCT02694536 2017-03-24
A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT02854072 2016-11-22
A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients
Samsung Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT02506842 2016-08-11
Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection
Fudan University
Phase 3 Unknown
NCT01360853 2016-08-04
ONTRAC
Traws Pharma, Inc.
Phase 3 Completed
NCT00574275 2016-06-07
VANILLA
Sanofi
Phase 3 Terminated
NCT00416507 2016-05-30
Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Federation Francophone de Cancerologie Digestive
Phase 3 Completed
NCT00634725 2015-12-11
Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Completed
NCT00075686 2015-11-17
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT00031837 2015-10-14
Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
University of Rochester
Phase 3 Terminated
NCT02355119 2015-02-04
GIP-2
Azienda Ospedaliero, Universitaria Pisana
Phase 3 Unknown
NCT01586611 2014-10-02
Panc001
AHS Cancer Control Alberta
Phase 3 Unknown
NCT00303758 2014-03-04
Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Federation Francophone de Cancerologie Digestive
Phase 3 Completed
NCT00058201 2013-12-18
Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00005869 2013-12-04
Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00005870 2013-12-04
Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
National Cancer Institute (NCI)
Phase 3 Unknown